Table 4.
MiRNAs associated with clinical outcome in the present study and reported relevance to CRC.
| MicroRNA | Present study | Differential expression (literature) | Prognosis/clinical outcome (literature) |
|---|---|---|---|
| miR‐106a | High levels in plasma associated with lack of response in mCRC patients treated with 5‐Fu/oxaliplatin | Upregulated in tumor (Arndt et al., 2009; Catela et al., 2013; Monzo et al., 2008; Ng et al., 2009; Schetter et al., 2008; Volinia et al., 2006) | High expression levels in tumor associated with poor survival in a test cohort (Schetter et al., 2008) |
| Upregulated in tumor of mCRC patients compared to CRC patients without metastases (Feng et al., 2012) | Downregulation in tumor associated with shorter DFS and OS (Diaz et al., 2008) | ||
| Upregulated in stool samples from patients with CRC or adenomas (Link et al., 2010) | Upregulation in tumor of patients without metastases associated with shorter metastasis‐free survival (Feng et al., 2012) | ||
| miR‐130b | High levels in plasma associated with lack of response in mCRC patients treated with 5‐Fu/oxaliplatin | Upregulated in tumor (Arndt et al., 2009; Monzo et al., 2008) | Not reported in CRC |
| miR‐484 | High levels in plasma associated with lack of response in mCRC patients treated with 5‐Fu/oxaliplatin | Highly expressed in sera from patients with mCRC compared to controls, but lower expressed than controls in early stage (I–II) patients (Hofsli et al., 2013) | Not reported in CRC |
| miR‐148a | High levels in plasma associated with shorter PFS in mCRC patients treated with 5‐Fu/oxaliplatin | Upregulated in stage II tumors (Monzo et al., 2008) | Low expression in tumor associated with poor prognosis in stage III patients treated with 5‐Fu‐based adjvant chemotherapy. |
| Downregulated in stage III and IV tumors compared with stage II tumors (Takahashi et al., 2012) | Low expression was also associated with lack of response and poor survival in mCRC patients treated with 5‐Fu/oxaliplatin (Takahashi et al., 2012) | ||
| miR‐27b | High levels in plasma associated with shorter PFS in mCRC patients treated with 5‐Fu/oxaliplatin | Not reported in CRC | High levels in tumor associated with lack of response to 5‐Fu/oxaliplatin in a mCRC test cohort (Rasmussen et al., 2013) |
| miR‐326 | High levels in plasma associated with shorter PFS and OS in mCRC patients treated with 5‐Fu/oxaliplatin | Not reported in CRC | Not reported in CRC |
Abbreviations: CRC = colorectal cancer, mCRC = metastatic colorectal cancer, DFS = disease‐free survival, PFS = progression‐free survival, OS = overall survival.